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The apparent predicament of the representative chemotherapy for managing respiratory distress 
calls for an obligatory deliberation for identifying the pharmaceuticals that effectively counter 
the contemporary intricacies associated with target disease. Multiple, complex regulatory 
pathways manifest chronic pulmonary disorders, which require chemotherapeutics that produce 
composite inhibitory effect. The cost effective natur l product based molecules hold a high 
fervor to meet the prospects posed by current respiratory-distress therapy by sparing the tedious 
drug design and development archetypes, present a robust standing for the possible replacement 
of the fading practice of poly-pharmacology, and ensure the subversion of a potential disease 
relapse. This study summarizes the experimental evidences on natural products moieties and 
their components that illustrates therapeutic efficacy on respiratory disorders. 















The chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), 
pulmonary sarcoidosis, asthma, pneumoconiosis, and lu g cancer pose major healthcare and 
economic strain across the globe. As per the annual report by World Health Organization (WHO) 
on ‘The Global Impact of Respiratory Disease’, COPD alone claims a global morbidity of 65 
million, including 3 million annual mortalities. The figures for asthma further raise the alarm 
with 334 million people suffering from the disease, which includes 14% of children [1]. Notably, 
pneumonia; caused by bacteria streptococcus pneumonia raises the mortality rate among children 
below 5 years of age. Tuberculosis, a chronic respiatory ailment caused by bacteria 
mycobacterium tuberculosis affects 10 million people annually, out of which 1.4 million lose 
lives. In addition, lung cancer represents a fatal, yet most common neoplasm claiming roughly 2 
million lives annually [2].  
The pathophysiology of COPD manifests chronic inflammation in the lung parenchyma 
mediated by macrophages, neutrophils, and cytotoxic (CD8+) T lymphocytes. The subsequent 
fibrosis results in narrowing of small airways and obliteration of parenchyma by proteases. 
Reportedly, the development of COPD focused precision medicine faces considerable challenges 
due to dearth of animal models for preliminary drug testing, and due to a lack of information 
about the surrogate markers for monitoring the efficacy of rationally designed drugs [3]. 
Bronchial asthma, an inflammatory condition develops due to the abnormal activity of enzymes 
and prostanoids [4], coupled with oxidative stress in the airways resulting in hypertrophy and 
hyperplasia of bronchial smooth muscles, hyper-respon iveness and hypersecretion of mucins in 
the airway passages [5]. Besides the anti-asthma drugs targeting cysteinyl leukotrienes, 
immunoglobulin E, anticholinergics, and β-AR agonists, the contemporary chemotherapy 
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development efforts against asthma could not yield clinically efficacious results in the last 3 
decades [6]. The emergence of multi-drug resistance microbial strains tainted the drug 
development efforts directed at pneumonia and tuberculosis [7], which are emerging as leading 
cause of excessive and unregulated antibiotic consumption [8]. Similarly, adenocarcinoma 
presents the recurring and most prevalent cancer typ  among the various lung cancer forms [9].  
Various cell signaling pathway are involved in inflammatory and oxidative response, remodeling 
of extracellular matrix leading to asthma, COPD andpulmonary fibrosis whereas cell migration 
and proliferation pathway leading to lung cancer progression [10-13]. In asthma and COPD, 
oxidative stress leads to inflammation in airway by through redox sensitive transcription factor, 
nuclear factor (NF)-kappaB (NF-kB) pathway [14]. The activation NF-κB in cytoplasm and 
subsequent translocation to nucleus is induced by inflammatory cytokines such as interleukin 
(IL)-1β and tumour necrosis factor (TNF)-α whereas via activation of toll like receptors (TLRs) 
during pathogenic infections (bacterial or viral) [15]. Similarly, increase in transforming growth 
factor (TGF)-b by airway epithelial cells and inflammatory cells are involved in the pathogenesis 
of pulmonary fibrosis. High level of TGF-b results in activation, migration, and proliferation of 
resident fibroblasts. These fibroblasts can differentiation into activated myofibroblasts promoting 
abundant extracellular matrix (ECM) deposition and bnormal collagen build-up [16]. Likewise, 
activation of pathway such as epidermal growth factor receptor-tyrosine kinase, anaplastic 
lymphoma kinase (ALK), c-ros oncogene-1 (ROS1), programmed cell-death-1/program cell 
death ligand -1 (PD-1/PD-L1), mitogen activated protein kinases (MAPK), phosphoinositide 3-
kinases (PI3Ks) are involved in migration and proliferation pathway leading to lung cancer 
progression [17-21].  
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Various natural compound are able to target the cell-signaling pathway showing beneficial 
activity against respiratory disease (Figure 1). The natural products containing alkaloids, 
flavonoids and terpenes serve as storehouse of essential chemotherapeutics [22-24], which 
produce desirable effects against chronic respiratory ailments (Table 1). These also prompt the 
development of novel drug systems by providing suitable pharmacophores for producing 
optimum effect against the target pathways associated with the manifestation of respiratory 
disorders [25]. This review presents a succinct discus ion on the potential of natural product 
derived drugs based on alkaloids, flavones and terpenes for capping the conventional and 
emerging respiratory disorders.  
Alkaloids 
Lu et al. 2007; reported the medicinal properties of tetrahydroquinoline alkaloid ‘Antidesmone’  
(1, Figure 2) for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome 
(ARDS), which represent prolonged inflammatory disorders instigated by membrane 
lipopolysaccharide (LPS) present on gram-negative bacteria, characterized by lung parenchymal 
injury and interstitial edema [26]. The microbial LPS instigate neutrophil infiltration, and trigger 
the production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), 
mitogen-activated protein kinase (MAPK) [27], cyclooxygenase-2 (COX-2) [28], interleukin-1β 
(IL-1β) [29], inducible nitric oxide synthase (iNOS) [30], nuclear factor-kappa B (NF-κβ) [31] 
and interleukin-6 (IL-6) [32] at the target site, thereby inducing acute lung injury.  
Exposure with antidesmone significantly down-regulated MAPK and TNF-α signaling pathway 
and apparently lowered the expression of NF-κβ by offsetting the nuclear translocation of REL-
associated protein p65, responsible for its activation [33]. Interestingly, the antidesmone 
exposure demonstrated significant inhibition of pulmonary myeloperoxidase (MPO), the 
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biomarker for accumulation of neutrophils in the morbid lungs [34], further validating the 
therapeutic privilege of the alkaloid.  
Reportedly, cigarette smoke (CS) potentiates the redox imbalance by activating lung epithelial 
cells and macrophages, thereby resulting in chronic respiratory ailments [35]. The heightened 
oxidative stress caused by CS dissociates transcription factor Nrf2 from kelch-like ECH-
associated protein 1 (Keap1) [36], eventually translocating into nucleus followed by binding to 
antioxidant response elements (ARE). These events rgulate downstream gene expression for 
phase II detoxification enzymes such as glutamate cysteine ligase (GCL), glutathione S-
transferase (GST), and heme oxygenase 1 (HO-1)[37] , that promote in maintaining cellular 
redox balance [38]. Therefore, Nrf2 signaling pathways present potential therapeutic target 
against the physiological redox imbalance [39].  
Liu et al. 2020; investigated the therapeutic potential of six isosteroid alkaloids (2-7, Figure 2) 
obtained from F. cirrhosa bulbus against the CS induced oxidative stress in RAW264.7 
macrophages. Reportedly, the identified six test alkaloids significantly attenuated the production 
of reactive oxygen species (ROS), upregulated the lev l of antioxidant molecule glutathione 
(GSH), and promoted the Nrf2 induced expression of HO-1 protein. Notably, the presence of 
glucoside moiety at C-3 position in alkaloid 5, and absence of β-OH at C-17 position in alkaloid 
6 resulted in higher GSH/GSSG ratio. Similarly, the presence of β-CH3 substituent at C-20 
position in alkaloid 3 favored its efficacy and tolerable cytotoxicity. The presence of –OH 
substitution at C-3 position in all the test alkaloids demonstrated a paramount importance for 




Zhao et al. 2017; investigated the curative effects and pharmacokinetics of alkaloids 8-11, Figure 
2, obtained from A. scholaris on ovalbumin induced airways allergic inflammatory model [41]. 
Exposure to the test alkaloids lowered the levels of eukocytes and eosinophils, further confirmed 
by histopathological analysis of lungs. Notably, the est alkaloids downregulated the secretion of 
proinflammatory cytokine IL-4, a key mediator of allergic responses eventually resulting in a 
significant reduction of pulmonary eosinophils, and balancing the rise of immunoglobulin E 
(IgE) in serum.  
Importantly, the animal models administered with the est alkaloids 3 times a day demonstrated 
lower levels of eotaxin in the serum. Eotaxin overexp ssed in the serum and airways of 
asthmatics serves as a biomarker for the pathogenesis of chronic asthma [42]. Therefore, its 
elimination from the systemic circulation in the morbid groups further validates the anti-asthma 
efficacy of test alkaloids. The administration of ttal alkaloids produced marked effect as 
compared to the single test alkaloid, hence confirming a synergistic effect. Moreover, these 
alkaloids proved useful for the treatment of post-infectious symptoms in animal models by 
mitigating the levels of inflammatory cytokines followed by down-regulation of the expression 
of IL-6. Histopathological examination of the morbid lungs further confirmed these observations 
[43]. Liu et al. 2015; isolated quinazoline alkaloids 12-14, Figure 2, from the aerial parts of 
Peganum harmala L [44], and tested their antitussive, expectorant, d bronchodilating effects in 
animal models.  
The alkaloids effectively lowered the symptoms associated with capsaicin induced acute 
pulmonary inflammation at doses 5, 15, and 45 mg/ k, compared to codeine phosphate 
administered at 30 mg/ kg. The test alkaloids appreciably promoted expectorant activity as 
indicated by phenol red secretion in mice trachea, compared to the standard drug ammonium 
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chloride. Further, the bronchodilating test verified that the test alkaloids considerably prolonged 
the pre-convulsive times in animal models, superior to the standard drug aminophylline, thereby 
validating the potency of these alkaloids for treating bronchial asthma.  
Alkaloids from Cissampelos sympodialis ‘warifteine’ (15, Figure 2) display notable efficacy in 
airway hyperreactivity in animal model of asthma [45]. Oral pretreatment of animal models with 
the test alkaloid warifteine significantly reduced the allergen induced airway hyperreactivity 
(AHR) to inhaled methacholine. Moreover, it also reduced the IL-13 levels in bronchoalveolar 
lavage, which serves as the key regulator of AHR [46]. The test alkaloid checked the ovalbumin 
(OVA)-induced eosinophil intrusion in the tissues, and downregulated the mucus production and 
subepithelial fibrosis. Further analysis of airway mucins by periodic acid-Schiff (PAS) staining 
revealed OVA induced metaplasia and mucus accumulation in animal models, which reduced 
significantly after warifteine administration.  
Kim et al. 2015; reported attenuation of IL-4 and eotaxin-2 mediated eosinophilic airway 
inflammation in asthmatic animal models by the alkaloid ‘chelidonine’ (16, Figure 2) isolated 
from Chelidonium majus [47]. The test alkaloid significantly suppressed the level of eosinophils 
in the airways, in addition to downregulation of eotaxin-2, interleukins, and cytokines in the 
bronchoalveolar lavage fluid. Notably, chelidonine treated animal models exhibited considerable 
decrease of CD4+ and CD8+ T cells, Gr-1+ /CD11b+ and 351 CD3/CCR3+ positive cells, which 
otherwise intensify inflammation process by secreting Th2 cytokines and degranulation of 
eosinophils [48]. Histological analysis suggested marked attenuation of OVA-induced eosinophil 
subversion, goblet cell hyperplasia, and accumulation of collagen in ling tissues in the presence 
of chelidonine. These findings validated the theraputic potency of this alkaloid in the treatment 
of pathologic inflammatory disorders associated with respiratory airways.   
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Alkaloids 17 and 18 (Figure 2) obtained from Pericarpium Citri Reticulatae reportedly exhibit 
appreciable anti-asthmatic activity. The administration of alkaloids in animal models with 
histamine induced asthma, downregulated eosinophils expression in bronchoalveolar lavage fluid 
and serum along with notable attenuation of IgE, IL-4 and IL-5. The alkaloid demonstrated 
spasmolytic effects on acetylcholine chloride-induced contractions in the animal trachea [49]. 
Kim et al. 2019; identified natural bis-benzylisoquinoline alkaloids 19, 20 and 21 (Figure 2) 
form stephania tetrandra, which inhibited human coronavirus OC43 infection of MRC-5 human 
lung cells at its early stages.  
Coronaviruses infect the respiratory tract thereby manifesting severe conditions such as 
bronchiolitis, and pneumonia [50]. The test alkaloids reportedly restricted the replication of 
human coronavirus OC43, restrained the expression of viral protein and virus-induced response 
of the host MRC-5 cells. Notably, the alkaloid 19 (Figure 2) activated the p38 Mitogen-Activated 
Protein Kinase (MAPK) pathway in the virus infected cells, which eventually improved their 
viability with minimal signs of cytotoxicity. The MRC-5 cells exposed to the test alkaloids 
showed negligible expression of proinflammatory cytokines, which are otherwise upregulated by 
the virus infection [51]. 
Deep-water sponges of the genus Pakina yield therapeutic alkaloid 22 (Figure 3), which 
displayed considerable bactericidal efficacy against Mycobacterium tuberculosis strain 
CDC1551. The test alkaloid Plakinamine P reportedly inhibited actively growing bacterial strain 
by 98 %, and dormant non-replicating bacteria by 67 %. The test alkaloid, being structurally 
similar to cholesterol and bearing undegradable sid chains allegedly inhibits the cholesterol 
catabolism pathway in the host microbe, which is essential for its survival and for the persistence 
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of ensuing infection. In addition, the metabolic breakdown of test alkaloid by cholesterol 
degradation pathway yields toxic products fatal to the host microbe [52].  
Coronaridine alkaloid 23 (Figure 3) isolated from Tabernaemontana ternifolia displayed marked 
antibacterial potency against Mycobacterium tuberculosis strain H37Rv with IC50 = 82.64 µg/ 
ml. The activity, however was lower than the commercial drug rifampicin (IC50 = 0.05 µg/ ml) 
[53]. Chen et al. 2017; isolated the alkaloid ‘Talaramide A’ (24, Figure 3) from Talaromyces sp. 
(strain HZ-YX1) and investigated its antimycobacterial potency by targeting mycobacterial 
protein kinase G (PknG), which plays a key role in the persistent localization of mycobacteria in 
macrophages. The alkaloid displayed significant inhibition of PknG with IC50 = 55 µM, thereby 
validating its potential for the treatment of chronic tuberculosis [54].  
Besides several contemporary targets for capping tuberc losis, shikimate pathway represents the 
most recently identified means for the survival of mycobacterium. MtSK, one of the key 
enzymes associated with the shikimate pathway mediates the phosphorylation of shikimate 
substrate by abstraction of phosphate group from adenosine triphosphate (ATP) thereby 
producing shikimate-3-phosphate and adenosine diphosphate products. Manzamine alkaloids 25, 
26 and 27 (Figure 3) isolated form Indo-Pacific sponge, Acanthostrongylophora sp. present 
mixed noncompetitive inhibition of MtSK enzyme. The kinetic profiling suggested that the
inhibition of target enzyme occurred via two-step mechanism where the isomerization of 
preliminary EI complex results in highly unstable EI* intermediate. Notably, the alkaloid 25c 
(Figure 3) due to 6-cyclohexamide substitution displayed superior potency compared to the peers 
with inhibition constant Ki = 0.06 µM [55]. Further research on marine sponge D ndrilla nigra 
for the identification of MtSK inhibitors led to the discovery of 3,4-diarylpyrrole alkaloids: 
Denigrin A, B and C (28, 29 and 30; Figure 3) [56].  
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Maarisit et al. 2017; identified the cyclic 3-alkyl pyridinium dimer alkaloids 31 (Figure 3) with 
antimycobacterial properties from the marine sponge Haliclona sp. [56]. Also referred to as 
cyclostellettamines when isolated from sponge Pachychalina sp., the test alkaloids with longer 
alkyl chains connecting the pyridinium moieties exhibited excellent activity against 
Mycobacterium Tuberculosis strain H37Rv [57]. The precise mechanism of action for the test 
alkaloids 31 (Figure 3) is still under investigation. Besides the active mycobacterium, the non-
replicating persistent Mycobacterium tuberculosis pathogen requires uninterrupted treatment for 
several months to prevent the relapse of disease [58]. 
The dormant mycobacterium requires hypoxic conditions for survival and displays considerable 
resistance against the representative drugs [59]. The marine sponge Aaptos sp. served as an 
excellent source for the isolation of aaptamine alkaloids 32 to 38 (Figure 3). Oxygen depletion 
instigated dormancy response of the mycobacterium in the form of resistance towards the 
antibiotic isoniazid served as the model for evaluating the anti-dormant mycobacterial efficacy of 
the test alkaloids. The test alkaloids displayed highly effective anti-dormant mycobacterial 
activity with IC50 in the range 1.5-6.25 µg/ ml. Further investigations suggested that the 
presence of carbonyl groups at C-3 and/ or C-9 position of the candidate alkaloids played a 
critical role in the expression of bioactivity against non-replicating dormant Mycobacterium 
tuberculosis [60]. These alkaloids formed the basis of identification of suitable pharmacophores 
for rationally designing the pharmaceuticals against dormant mycobacterium.    
2. Flavonoids 
Zhi et al. 2020; investigated the efficacy of flavonoids 39-46 (Figure 4) isolated form Scutellaria 
baicalensis against influenza A virus (IAV) induced acute lung i jury (ALI). The inactive form 
of test flavonoids metabolized in vivo to anti-complimentary active metabolite aglycones 47-53 
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(Figure 4) by the enzyme β-glucuronidase secreted by the epithelial cells, which demonstrated 
superior absorption into IAV-induced ALI animal models [61]. The infected animal models 
demonstrated a better metabolic transformation of the test flavonoids to active metabolites, with 
elevated levels in lungs and intestine, with higher content in the latter suggesting that the test 
flavonoids reach intestine first and then transformed to active metabolites before finally 
becoming a part of systemic circulation. The active m tabolites 47-53 after reaching the lungs 
reportedly downregulate the levels of TNF-α, IL-6, monocyte chemotactic protein (MCP-1), 
while raising the levels of IL-10 and interferon-γ (IFN-γ), and considerably lowered the 
production of nitric oxide (NO) from lipopolysaccharide (LPS)-stimulated RAW264.7 cells 
thereby attenuating the activity of target virus [62]. 
Flavonoids 54-56 (Figure 4) extracted from Houttuynia cordata appreciably mitigated acute lung 
injury caused by H1N1 virus [63]. The animal models xposed to test flavonoids maintained the 
morphology of diseased lung microstructures, attenuated the penetration of proinflammatory 
factors MCP-1, IL-8, TNF-α, and malondialdehyde that play crucial role in therecruitment of 
macrophages and neutrophils at the site of stimulus [64]. However, the levels of interferon-β 
elevated, which played a key role in restricting the replication of virus [65]. In addition, the 
expression of TLR3/4/7 and level of NF-κ β p65 phosphorylation lowered in the lung tissues, 
which are associated with heightened activation and secretion of interferon-β [66]. Hence, the 
test flavonoids directed anti-inflammatory therapy served deliberated approach for countering 
IAV induced pathological processed manifesting acute l ng injury. Reportedly, the flavonoids 54
and 56 (Figure 4) displayed enhanced biocidal potential against Mycobacterium tuberculosis 
H37Rv strain with IC50 = 6.25 and 25 µg/ ml respectiv ly [67]. The biocidal potential of the test 
flavonoids proved better than the standard anti-TB drugs isoniazid and rifampicin.  
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Besides numerous efforts entailing anti-TB drug development, the emergence of drug-resistant 
mycobacterial strains necessitated the identification of novel drug targets by highly efficacious 
pharmacophores. MtPKnG, a protein kinase G produced by Mycobacterium tuberculosis 
represents serine/ threonine kinase enzyme, which prolongs the survival rate of the bacterium in 
host macrophages by preventing the phagosome-lysosome fusion [68]. The enzyme mediates 
phosphorylation of proteins associated with essential signal transduction pathways in bacteria 
and allegedly sustains the tuberculosis infection in the host [69]. Notably, the MtPKnG enzyme 
prompts anti-TB drug resistance in mycobacteria and serves as a key component for 
mycobacterial biofilms production. Hence, it forms a desirable target for anti-TB drug discovery 
against resistant mycobacteria.  
Qasaymeh et al. 2019; reported bioactive flavonoids 57-59 (Figure 4) isolated from 
Pelargonium sp. with excellent binding affinity towards MtPKnG [70]. The in silico docking 
analysis confirmed the interactions of flavonoid 57 (Figure 4) with target enzyme MtPknG via 
H-bonding (<2.5 Å) with essential residues E233, E280, S239 and Q238. Similarly, the -OH 
groups present on B-ring of the test flavonoid 58 (Figure 4) showed H-bonding interaction with 
the residues K181, D293, and its flavone moiety interacted with Ala158 and Ile157 residues of 
the target enzyme. Nevertheless, the test flavonoid 59 (Figure 4) exhibited significant H-bonding 
interactions with residues K181 (2.498 Å), D293 (2.213 Å) and Q238 (2.278 Å) and hydrophobic 
interactions with the active site residues A158, I157, I165, I292 and M283 of the target MtPknG 
enzyme. These naturally occurring flavonoids hold tremendous potential for rationally designing 
pharmaceuticals and chemical therapeutics, essentially for targeting multidrug-resistant TB.             
The drug resistance in microbes arises due to over-activity of the membrane bound efflux pumps 
that prevent the drug internalization in cells. The lack of clinically approved efflux pump 
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inhibitors further aggravate the disease pathogenesis. Polymethoxylated flavonoids 60-64 (Figure 
5) reportedly reduced the rifampicin resistance and adversely affected the survival of 
Mycobacterium tuberculosis. Importantly, the bioactivity of anti-TB drug isoniaz d enhanced in 
the presence of test flavonoids [71]. However, furthe  investigations could not quantify the 
insight mechanism for the behavior of test flavonoids towards mycobacterium efflux pumps. 
Reportedly, the flavonoid 60 (Figure 5) considerably attenuated AHR, and reduce the 
expression of airway eosinophils and Th2 cytokines, whereas it amplified the levels of 
transforming growth factor-β1 (TGF-β1) in the bronchoalveolarlavage (BAL) fluids in OVA-
sensitized animal models.  
The administration of flavonoid 60 (Figure 5) also mitigated the collagen deposition in sub-
epithelium, and suppressed goblet cell hyperplasia. Hence, the test flavonoid served as 
bradykinin antagonist and diminished the principal thophysiological characteristics associated 
with allergic asthma [72]. Jeon et al. 2017; isolated flavonoid 65 (Figure 5), which exerted 
bactericidal effect on drug-resistant mycobacterium tuberculosis H37Rv strain. The test 
flavonoid reportedly inhibited the release of proinflammatory interleukins and attenuated the 
expression of TNF-α. The test flavonoid 65 (Figure 5) exhibits high affinity binding to M. 
tuberculosis β-ketoacyl acyl carrier protein synthase III (mtKASIII) enzyme via interactions of 
A-ring 2-OH and B-ring 4-OH groups of the flavonoid with N261 and C122 residues [73]. 
Importantly the open chain structure of phloretin permits membrane permeability against the 
mycobacterial cell wall, which protects the microbe from antibiotics and allows its persistence 
and proliferation in macrophages.  
The flavonoids 66 and 67 (Figure 5) isolated from Mosla chinensis Maxim exerted inhibitory 
potential against H1N1 influenza virus mainly by downregulating the expression of the host TLR 
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signaling pathways [74]. In addition, the upregulation of critical factors (IL-6, TNF-α, IFNγ, and 
NO) and suppression of IL-2, SOD and cytokine GSH caused significant reduction of virus 
instigated inflammatory damage to lung tissues. Pawar et al. 2020, investigated the anti-
tubercular activity of flavonoids 68 and 69 (Figure 5) by targeting glutamate racemase enzyme of 
the microbe associated with the synthesis of membrane peptidoglycans by transforming L-
glutamate to D-glutamate.  
The enzyme also plays a key role in DNA gyrase sequestration. The test flavonoids introduced 
deformations in the secondary and tertiary structure of the target enzyme by attenuating the 
helical contents, which manifested morphological changes in the microbial membrane. The 
interaction of test flavonoids with active site residues D12, C75, C185, and H187; present at the 
substrate binding site of glutamate racemase enzyme prompted its inhibition [75]. The flavonoids 
70, 71 and 72 (Figure 5) proved highly efficacious for capping severe acute respiratory syndrome 
(SARS) caused by coronaviruses by inhibition of 3C-like proteases (3CLpro), responsible for 
autocleavage of viral polyproteins essential for vial propagation. The test flavonoids 
significantly blocked the enzyme activity by interacting effectively with the substrate-binding 
site via hydrophobic aromatic rings and hydrophilic –OH groups [76].  
Mulberry root bark served as principal component for the isolation of prenylated flavonoid class 
‘sanggenols’ 73-77 (Figure 5) bearing dual activity against influenza virus and Streptococcus 
pneumoniae. The prenylated flavonoids displayed high physiological tolerance while having an 
inhibitory potential superior to the standard drug olestamivir against the target neuraminidase 
(NA) enzyme, which sustains lethal synergy between the influenza virus and S. pneumoniae 
assisting the sustenance and longevity of the both [77].   
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In virus, the NA enzyme promotes reproduction and spread, whereas in the bacterium, NA 
enzyme facilitates the cleavage of sialic acid from glycoproteins present on the cell surface 
thereby affording receptors for attaching of microbe hence providing the host cell nutrients for 
further growth and colonization [78]. Hence, it makes a desirable target for attenuating the 
pathogenesis caused by Influenza virus and S. pneumoniae. These events allow the release of 
virus from infected cells and provides defense against representative drugs. The prenylated 
flavonoids effectively break this synergism thereby preventing the bacterial coinfection in the 
subjects with influenza [79].      
3. Terpenes 
Hirota et al. 2012, evaluated the potential of monoterpene limonene (78, Figure 6) in treating 
airway inflammation. Reportedly, limonene inhibits attenuates the allergic airway inflammation 
in Dermatophagoides farina-treated animal models, mainly by mitigating reactive oxygen 
species. The exposure to limonene significantly reduc  the levels of interleukins-3/ 5, eotaxin, 
MCP-1, TGF-β in the bronchoalveolar lavages. In addition, the limonene administration 
abrogated gblet cell metaplasia, airway fibrosis, and thickness of the airway smooth muscles. 
These finding validated the candidature of limonene as prophylactic agent in asthma treatment 
[80].  
Alavinezhad et al. 2017; investigated the therapeutic effect of carvac ol (79, Figure 6) on asthma 
subjects. The carvacrol exposure induced relaxant effect on the tracheal smooth muscles by 
reducing the total WBC, neutrophil, monocyte and eosin phil count in the blood and 
bronchoalveolar lavage fluid of the sensitized animal odels. The relaxant effect of carvacrol 
occurs due to the significant attenuation of pro-inflammatory biometabolites in systemic 
circulation [81]. Boskabady et al. 2013; validated the preventive effect of carvacrol on tracheal 
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responsiveness in ovalbumin treated animal models. Interestingly, the treatment of animal 
models with carvacrol considerably lowered the levels of nitric oxide in serum, produced by 
endothelial nitric oxide synthase, which reportedly triggers plasma extravasation and lung edema 
[82]. Similarly, the higher levels of iNOS-derived nitric oxide raises vascular permeability, 
instigates mucus hypersecretion, and worsenes the inflammatory cell permeation, and epithelial 
cell damage that contribute to asthma pathology [83].  
Wan et al. 2017; investigated the therapeutic effects of thymol (80, Figure 6) in animal models 
with LPS-induced acute lung injury. The LPS-challeng d animals showed improved pathological 
changes in lung tissues on thymol exposure. Reportedly, the LPS-induced influx of the 
inflammatory cells and metabolites, interlukins and TNF-α attenuated in bronchoalveolar lavage 
fluid on thymol administration. In addition, thymol a so restrained the LPS-mediated upsurge of 
MDO and MPS levels, and considerably lowered the activity of SOD thereby pausing the 
activation of NF-κB in the lungs [84]. These neutrophil localized enzymes primarily influence 
the adhesion and margination of neutrophils in the lung thereby causing severe lung injury.  
Mohammadi et al. 2018; evaluated immunomodulatory effects of thymol in mitigating oxidative 
stress associated with asthma immunopathogenesis. Thymol-exposure attenuated the levels of 8-
OHdG, an oxidative marker in asthma and carbonyl protein released by peroxidases from 
eosinophils in the airway passages, which elevates mu ine secretion, overexpresses cytokines 
and elevates apoptosis of epithelial cells lining airw y passages. Reportedly, thymol affords 
considerable cytoprotective effect against the oxidative stress and moderately reinstates the 
defective trace element levels in asthma [85].  
Gabri et al. 2019; studied the ameliorative effects of thymoquinone (81, Figure 6) on the LPS-
induced pulmonary vascular damage. The protective effect appears because of the 
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downregulation of proinflammatory cytokines and interleukins in the presence of thymoquinone. 
In addition, thymoquinone administration attenuated the expression of NF-κB, TNFα, and IL-1β 
in the respiratory airways produced due to the LPS sensitization [86]. Thymoquinone also 
protects against lung damage caused by cigarette smoke by mitigating the expression of 
proinflammatory leukotrienes, prostaglandins, thromb xanes and importantly IL-1β, the 
principal biomarker cytokine in cigarette smoker’s lung [87]. Su et al. 2016; evaluated the 
protective effects of thymoquinone in asthma animal models. Thymoquinone reportedly 
attenuated the expression of IL-4/5 and improved the expression of platelet endothelial cell 
adhesion molecule1 (CD31) and α-smooth muscle actinalpha (α-SMA) in ovalbumin-sensitized 
animals. In addition, thymoquinone deactivated VEGFR2-PI3K-Akt pathway and upregulated 
the expression of Slit glycoprotein-2 (Slit-2), whic  validates its anti-neoangiogenesis effect in 
asthma amelioration [88].  
Qamar et al. 2008; investigated farnesol (82, Figure 6) for the effective amelioration of lung 
injury caused by cigarette smoke, known to cause pulmonary emphysema, COPD, and 
pulmonary fibrosis. The isoprenoids such as farnesol possesses excellent anti-nociceptive and 
chemopreventive potency and demonstrates protection against chronic lung inflammation, 
oxidative stress and lung injury caused by cigarette smoke intoxicants. The prophylactic 
treatment with farnesol showed lung-protective sympto s by lowering LDH levels, and lowered 
activity of reduced glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx) 
and catalase enzymes. The lowered H2O2 content in lung tissues further validated the 
cytoprotective effects of lung tissues against cigarette smoke [89]. Farnesol proved efficacious in 
the alleviation of benzopyrene-induced respiratory stress in animal models. Farnesol also 
sustained optimal levels of phospholipids and altered the catalytic activity of benzopyrene 
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enzymes NADPH–cytochrome P450 reductase, glutathione S-transferase (GST) and microsomal 
epoxide hydrolase (mEH) in the lung tissues of animl odels. These findings suggested the 
protective role of farnesol against benzopyrene induce  lung inflammation, edema, and epithelial 
damages in subject animals [90].  
Gordien et al. 2009; reported the antimycobacterial activity of terpenes 83, 84 and 85 (Figure 6) 
isolated from Juniperus communis L. Reportedly, the terpene 84 (Figure 6) displayed enhanced 
activity against H37v strain of Mycobacterium tuberculosis with IC50 = 73.7 µM, and against 
the isoniazid-, streptomycin- and moxifloxacin-resistant strains with IC50 in the range 38.4-83.4 
µM. The terpenes 83, and 84 (Figure 6) demonstrated excellent activity against rifampicin-
resistant variants with IC50 = 24 µM and 20.2 µM respectively. The terpene 85 (Figure 6) 
displayed noticeable inhibitory activity against Mycobacterium aurum with IC50 = 13.2 µM; 
however with a low selectivity index which indicated physiological toxicity [91].      
Andrographolide (86, Figure 7) reportedly ameliorates LPS-induced acute l ng injury by an 
effective downregulation of MAPK and NF-κB pathways, which regulate the production of 
inflammatory cytokines such as TNF-α and IL-6 in bronchoalveolar lavage fluid [92]. The anti-
oxidative potency of andrographolide effectively restores the steroid sensitivity for blocking 
LPS-induced production of IL-27 and airway hyper-responsiveness. Moreover, andrographolide 
considerably restored the levels of nuclear HDAC2 protein and their total activity, whereas it 
contracted the total activity of histone acetyltransferase/HDAC in the animal lungs exposed to 
LPS/IFN-γ. These events occurred due to the suppression of phosphorylation of 
PI3K/Akt/HDAC2, and the upregulation of antioxidant transcription factor NF erythroid-2–
related factor 2 level [93].  
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Sulaiman et al. 2018; presented the beneficial effects of andrographolide in offsetting toluene 
diisocyanate (TDI)-induced occupational asthma and berrant distribution of E-cadherin in the 
airways. TDI represents the major cause of occupation l asthma culminating 15 % of the global 
asthma deaths. The exposure of the respiratory airways to oxidants results in epithelial cell 
necrosis and functional impairment due to defective expression of adherens junction proteins 
such as E-cadherin and β-catenin. Hence, E-cadherin maintains epithelial barrier stability of the 
airway mucosa and allergic sensitization, which lowers in asthma condition thereby promoting 
the infiltration of oxidants via defected airway epithelium [94]. Andrographolide exposure 
maintained airway integrity by reversing the distribut on of aberrant airway epithelial E-cadherin 
and β-catenin. In addition, it led to the attenuation of TNF-α induced production of oxidants and 
ROS via upregulation of Nrf2 through Akt phosphorylation [95].  
Lampronti et al. 2017; reported therapeutic potential of β-sitosterol (87, Figure 7) extracted from 
Nigella arvensis L., in mitigating the expression of cytokine genes in cysti  fibrosis epithelial 
cells lining bronchi. The test terpene significantly reduced the expression of neutrophilic 
chemokines IL-8, GRO-α, and GRO-β in LPS-sensitized human bronchial epithelial cells. These 
chemokines play a critical role in the recruitment of neutrophils in the lungs inflamed with cystic 
fibrosis. The investigations suggested that β-sitosterol partially inhibited LPS-triggered 
activation of Protein Kinase C isoform alpha, associated with transmembrane signaling for the 
activation of the expression of IL-8 gene in bronchial epithelial cells. Hence, β-sitosterol 
effectively mitigates the chronic lung inflammation i  the patients with cystic fibrosis [96]. 
Further investigations suggested the attenuation of pulmonary fibrosis by β-sitosterol, by 
preventing the abnormal accumulation of extracellular matrix (ECM), manifesting deleterious 
effects to the alveolar epithelium resulting in epithelial–mesenchymal transition (EMT). β-
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sitosterol, reportedly displayed anti-fibrotic effect while inhibiting EMT by downregulating the 
expression of transforming growth factor-β1 (TGF-β1). Notably, treatment with β-sitosterol 
convincingly blocked TGF-β1-induced protein expression of EMT markers, N-cadherin, 
vimentin, and E-cadherin [97].  
Kim et al. 2012; studied effect of Ursolic acid (88, Figure 7) on ovalbumin-induced airway 
inflammation and airway hyper-responsiveness in anim l asthma models. Ursolic acid displayed 
significant inhibition of airway inflammation via suppression of Th2 cytokines such as IL-5, IgE, 
and CCR3 expression [98]. Ursolic acid reportedly displays chemotherapeutic effect on COPD, 
and provides protection against cigarette smoke induce  cell injury by suppressing the lung 
tumor metastasis [99]. The therapeutic effect of allergic asthma arises due to increase in the 
expression of PPARg and attenuated GATA-3 and STAT6 expression, resulting in a decrease of 
antigen-induced Penh, eosinophilia, lung inflammation, and the production of cytokines and 
antigen-specific IgE that play vital role in coordinating and intensifying the allergic 
inflammation in asthma [100]. Reportedly, the treatment with ursolic acid alleviates emphysema 
instigated by cigarette smoke by PERK pathway, as well as Nrf2 pathway [101]. The activation 
of PERK discourages protein synthesis via phosphorylation of eukaryotic translation initiator 
factor, thereby causing a selective translation of ATF4, which controls the expression of critical 
apoptotic association genes.  
Nuclear erythroid-related factor 2 (Nrf2) represent a transcription factor regulating several 
antioxidant and detoxification genes [102]. Nrf2 signaling pathway plays a critical role in 
cigarette smoke-induced emphysema. Reportedly, ursolic acid demonstrates protective effects 
against cigarette smoke-induced emphysema through PERK andNrf2 signaling pathway. Further 
investigations on beneficial pulmonary effects of ursolic acid suggested that the terpene 
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effectively alleviates cigarette smoke induced emphysema and airway remodeling involving 
unfolded protein response (UPR) pathways by suppression of ERS-associated apoptosis, and 
downregulation of IGF1, TGF-β1, and p-Smad2/3 expression [103, 104]. These factors mediate 
bronchial epithelial and muscle cell regeneration in COPD patients through effects on airway 
vessel remodeling and muscle atrophy.  
Lee et al. 2010; appraised theanti-asthma potency of Betulinic acid (89, Figure 7) isolated form 
Forsythia viridissima. The terpene successfully paused the activity of histamine and 
phospholipase A2 in bronchoalveolar lavage fluid at a 12.5 mg/ kg dose. The activity of 
eosinophil peroxide (EPO) and eosinophil recruitment lowered at a dose of 25 mg/ kg. These 
metabolites act as the precursors of chronic inflamm tion in the airway passages [105]. Ekuadzi 
et al. 2017; further validated the potency of betulinic a id for the treatment of respiratory 
ailments, chiefly the carrageenan induced lung inflammation in animal models by successful 
inhibition of the production of proinflammatory chemokines and cytokines [106].  
Jiang et al. 2017; reported the beneficial effects of Oridonin (90, Figure 7) for capping acute 
respiratory distress syndrome (ARDS) in animal models. The test terpene notably mitigates the 
expression of inflammatory metabolites and factors such as TNF-α, IL-6, and NF-κB p56. 
Conversely, the expression of Iκ-B α augmented in lung tissues and bronchoalveolar lavage fluid 
[107]. Wang et al. 2016; further verified the protective effects of oridonin by studying its anti-
asthma potential in ovalbumin-sensitized animal models. Reportedly, oridonin sustains Th1/Th2 
cytokines balance in sensitized animal models and demonstrated anti-asthmatic effects in acute 





4. Clinical Significance 
Structurally diverse, plant derived natural products bear a privileged status in rational designing 
of commercially successful medicines. The identification of plant based natural molecules with 
therapeutic properties prompted systemic efforts to explore and commercially exploit the nature-
derived drugs for countering clinical intricacies associated with the chronic diseases [109]. The 
natural product based drugs present considerable commercial representation under various brand 
names, as well as a significant number of candidate mol cules in clinical trials [110]. However, 
the nature-derived molecules in chronic respiratory diseases present only a limited clinical 
profile, with even fewer molecules in commercial scaling [111].  
A randomized controlled trial conducted in 60 patients with moderate to severe asthma suggested 
the safety and efficacy of Squill oxymel (a popular Iranian medicine obtained from Drimia 
maritima). Squill oxymel was able to significantly increases the force expiratory volume (FEV) 1 
liter, FEV1%, FEV1/force vital capacity (FVC%), and maximal mid expiratory flow (MEF) as 
compared to placebo. There was a remarkable improvement in symptoms, activity, and total 
score in the patients administered Squill Oxymel but not in the placebo group. Moreover, there 
was no serious adverse observed except minor nausea nd vomiting reported in five patients in 
Squill oxymel group. This trail showed a strong potential of Squill Oxymel in terms of safety and 
efficacy for asthma patient [112]. Another double-bind randomized controlled clinical trial 
involving 85 asthma patients investigated whether plant stanol ester improves immune function 
in those patients. The effect of plant stanol added in soy-based yogurts in half of the patient on 
comparison with remaining half receiving control yogurt (placebo group) suggested considerable 
therapeutic results. It was observed that patients receiving plant based stanol ester group showed 
increased antibody titres against hepatitis A virus after 3 week [19% (P = 0.037)] and 4 wk [22% 
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(P = 0.030)] of vaccination. Likewise, there was a m rked depletion in plasma total IgE, TNF-α, 
IL-1β in plant-stanol ester group compared to placebo control. Furthermore, a correlation 
appeared between the increase in serum plant-stanol concentrations and decrease in IL-13 
concentrations as well as Th1 switch in the Th1/Th2 balance [113]. The alkaloids such as 
theophylline, lobeline, and narceine have been commercialized as adenovasin, citotal, and 
peneraj respectively for relieving chronic symptoms associated with asthma, however several 
molecules fail to clear the clinical trials prior t successful commercialization [114, 115].  
Sulforaphane is a derivative of broccoli and commonly found in cruciferous vegetables. A phase 
2 randomized trail conducted in 89 COPD patients were given either placebo or 25 µmoles or 
150 µmoles of sulforaphane orally for 4 wks. The changes in nuclear factor erythroid-2 related 
factor 2 (Nrf2) target gene expression in bronchial epithelial cells and alveolar macrophages as 
well as measurement of oxidative damage, airway inflammation, and pulmonary function tests 
were tested. However, sulforaphane did not induce the Nrf2 target gene expression and no 
significant anti-oxidant and anti-inflammatory activity appeared as compared to placebo control 
[116]. Thyme herb, ivy leaves and primose roots exhibit beneficial effects against acute 
bronchitis and productive cough [117].  
Gruenwald et al., 2005 and Kemmerich B. 2007 separately conducted a double-blind randomized 
control trial to study the efficacy and tolerability of thyme herb and primose root combination 
therapy In Gruenwald et al., 2005 study, the combinatio  therapy was administered as 1ml orally 
in 75 outpatient suffering with bronchitis while remaining 75 patients were given placebo. The 
combination therapy was effective in significantly reducing the bronchitis severity score leading 
to more patients with symptom free in combination therapy as compared to placebo group at the 
end of study. Both groups tolerate the treatment very well as there was no serious adverse events 
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observed [118]. Similarly in Kemmerich B study, 183 patients with acute bronchitis were given 
with 1 tablet of thyme-primose combination thrice a d y for 11 days and the efficacy was 
compared with placebo (N= 178 patients). There was a mean reduction of 67.1% of coughing fits 
in combination therapy group compared to 51.3% in placebo group on day 7 to 9. The 
combination therapy reduces the coughing fits to 50% two days earlier than placebo group. 
Further, no severe adverse events appeared in both groups, which concludes the well tolerability 
of thyme-primose combination therapy [119].  
Kemmerich B et al. 2006 further reported in another trial investigating the efficacy and 
tolerability of thyme herb and ivy leaves in acute bronchitis patient. Similarly, the safety and 
efficacy of alcoholic extract of Echinacea purpurea herb (95%) and root (5%) in a large 
population (755 healthy volunteer) over 4 month’s duration demonstrated significant therapeutic 
effects. The efficacy of extract to prevent the common cold episode when compared with 
placebo group showed beneficial activity against common cold by reducing the total number of 
cold episode as well as cumulated episode days. Furthermore, the extract was able to prevent 
enveloped virus infection. Regarding safety issue, 9% of participants in Echinacea extract treated 
group and 10% in placebo group showed adverse effect concluding the safety of Echinacea as 
non-inferior to placebo. The clinical trials evaluating the safety and efficacy of various natural 
product compounds in chronic respiratory disease are scarce. The limited clinical trials with few 
promising natural moieties need further validation with multiple evidence [120].  
In Table 2, we present the clinical studies on natural product-based molecules for countering the 





5. Conclusion and Future Perspectives 
Chronic respiratory disorders mainly arise due to the bronchial and pulmonary inflammation 
arising due to the heightened innate response causing an upsurge of proinflammatory 
metabolites, and over activity of enzyme such as cyclooxygenases, and lipoxygenases. The 
inhalation of toxicants manifests the recruitment of inflammatory cells in the bronchial and 
alveolar mucosa. The perseverance of nonspecific marophages and adaptive T-lymphocytes 
even after the prolonged stimuli cassation inappropriately instigates the memory cells of adaptive 
immunity, an event further maintained by dendritic cells, which also induce remodeling of lung 
tissue. In addition, the oxidative stress and disturbance in protease/ antiprotease balance deter the 
beneficial effects of corticosteroids in managing airw y inflammation.  
The ensuing effects include increased thickness of the bronchial wall leading to narrowing of the 
lumen, increased tone of bronchial smooth muscle leading to loss of elasticity and mucus 
oversecretion, proliferation of fibroblasts, detrimental extracellular matrix, and apoptosis in the 
endothelial cells. The involvement of multiple regulatory pathways in mediating respiratory 
disorders necessitates the development of multi-targe ing medications. The practice of 
polypharmacy holds considerable potential for effectiv ly managing the composite pulmonary 
maladies, considering the patient compliance. Mucoactive drugs such as ‘erdosteine’ combat 
broncho-obstructive symptoms by reinstating mucociliary clearance.  
Notably, erdosteine displays significant antibiotic effect thereby attenuating the bacterial load 
during the respiratory distress. Similarly, the pulmonary disorders caused by multidrug-resistant 
microbes such as mycobacterium tuberculosis, and streptococcus pneumoniae requires 
innovative pharmaceuticals with multifarious targeting potential. Reportedly, the isoniazid 
monotherapy or rifampicin or pyrazinamide bitherapy roved inadequate for the disease 
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management and resulted in its recurrent cycles. Hence, the recommended anti-TB regimen 
suggests polypharmacy as preliminary combination therapy of rifampin, isoniazid, pyrazinamide, 
ethambutol, and pyridoxine to prevent the recurrence of disease. Nevertheless, the amenability of 
the subjects to the combination of drugs, and the probability of microbial susceptibility to the 
administered doses raises compulsion for the identification of physiologically tolerable, novel 
pharmacophores for which the natural products present an ideal profile.     
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Table 1: Natural products showing effect in respiratory disorders 
S.No. Natural 
product 
Nature Chemical structure Pharmacological/ 











• Anti-inflammatory via 
reducing the levels of 
interleukin (IL)-6, TNF- α 





















• Anti-inflammatory via 








• Ameliorate oxidative stress, 
• Anti-inflammatory via 
downregulation of TNF-α 
and IL-6 levels 
[28] 







• Ameliorates allergic airway 
inflammation and hyper-
responsiveness by inhibiting 
the activation of NF-
κB signalling pathway  
[29] 







• Decrease in pro-
inflammatory cytokine 
(TNF-α and IL-6) levels, 
• Inhibit NF-κB signalling 
pathway, 
• Increase the level of 
antioxidants in the body, 
• Reduces viability of 
cancerous cells 
[30] 


















• Anti-carcinogenic properties 
[31] 










• Anti-inflammatory via 












• Inhibit MAPK and NF κB 
pathway 
• Reduces neutrophil 
inflammation 
• Inhibits LPS-induced TNF-α, 
interleukin-6. 
• Inhibits nitric oxide 
production in macrophages 
[33] 








• inhibits serum necrosis factor 
α, IL-1β, IL-6, nitric oxide 
(NO), IL-10  















• Suppress MAPKs and NF-
κB signaling pathway 
[35] 








• Inhibits TNF-α expression 
• Inhibits proliferation of 
tumor cells and promotes cell 
death by apoptosis 
[36] 












• Anti-inflammatory effect via 
suppressing neutrophilic lung 
inflammation 
[37] 














• Suppress the production of 
NO synthase  and ROS 
[38] 





• Sensitize tumor cells to 
chemotherapeutic agents by 
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Treatment of pulmonary 
arterial hypertension 
(PAH) in human 
subjects 
Upregulates levels 
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5. Carvacrol Origanum vulgare OH
 
Therapeutic effect on 














rhinosinusitis in human 
subjects 
Mucolytic agent in 













Alleviates symptoms of 
















inflammatory effects of 
oxidative stress in 
respiratory passages in 
Induces the 
expression of 
mucosal Phase II 
enzymes in the 
upper airway 
[132] 
human subjects passage 





O OH  
Prevention of 
deleterious 
cardiovascular events in 








disorders in COPD 
subjects 
[133] 
10. Pycnogenol Pinus pinaster Complex antioxidant 
compounds 
Relieves asthma 
inflammation in human 
subjects 
Inactivation of NF-





11. Linoleic acid Vegetable oils Polyunsaturated fatty acid Improves the airway 
hyper‐reactivity 
















Significant inhibition in 
the incidence and 
severity of nocturnal 
attacks, improvement of 
ventilatory functions in 







E2 and F2α and 
leukotriene D4; 
upsurge in IL‐10. 

































































































































































































20. Fangchinoline 21. Cepharanthine  

































a.  R = H (Manzamine E)










c. R1,  R 2 = H, cyclohexamide
(8-cyclohexamido-manzamine A)
(8-OH-manzamine A)
b.  R1,  R 2 = OH, H 









































































32. 33. 34. 35. 36. 37. 38.
(32-38)AAPTAMINES 





























































































































































































59. Populnin  





























60. Skullcapflavone II 61. Nobiletin 62. Tangeretin











































































































































90. Oridonin  





• Plant derived therapeutics for managing chronic respiratory disorders. 
• Activity of natural product based molecules on key regulatory pathways of COPD. 
• Preclinical evidence for the efficacy of natural product moieties.   
• Clinical significance of plant derived molecules in pulmonary distress.   
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